araag2/HINT huggingface dataset:
Clinical trial NCT00759876 (phase 2, status: terminated)
Conditions: duchenne muscular dystrophy
ICD codes: G71.01
Drugs: ataluren
SMILES: OC(=O)C1=CC=CC(=C1)C1=NOC(=N1)C1=CC=CC=C1F
Reason stopped: 
    terminated early because similar study with ataluren (ptc124-gd-007-dmd; nct00592553) exhibited
    lack of efficacy at the high dose (not due to safety concerns).
  
Eligibility criteria:

        Inclusion Criteria:

          -  Completion of ataluren treatment in the previous Phase 2a study (Protocol
             PTC124-GD-004-DMD).

          -  Ability to provide written informed consent (parental/guardian consent if
             applicable)/assent (if <18 years of age).

          -  Confirmed screening laboratory values within the central laboratory ranges.

          -  In participants who are sexually active, willingness to abstain from sexual
             intercourse or employ a barrier or medical method of contraception during ataluren
             administration and the 6-week follow up period.

          -  Willingness and ability to comply with scheduled visits, drug administration plan,
             study procedures, laboratory tests, and study restrictions.

        Exclusion Criteria:

          -  Treatment with systemic aminoglycoside antibiotics within 3 months prior to start of
             study treatment.

          -  Treatment with warfarin within 1 month prior to start of study treatment.

          -  Known hypersensitivity to any of the ingredients or excipients of the study drug
             (Litesse® UltraTM [refined polydextrose], polyethylene glycol 3350, Lutrol® micro F127
             [poloxamer 407], mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla,
             Cab-O-Sil® M5P [colloidal silica], and magnesium stearate).

          -  Exposure to another investigational drug within 2 months prior to start of study
             treatment.

          -  History of major surgical procedure within 1 month prior to start of study treatment.

          -  Ongoing immunosuppressive therapy (other than corticosteroids).

          -  Ongoing participation in any other clinical trial (except for sub-studies specifically
             approved by PTC Therapeutics).

          -  Clinically significant symptoms and signs of congestive heart failure (CHF) (American
             College of Cardiology/American Heart Association Stage C or Stage D).

          -  Prior or ongoing medical condition (for example, concomitant illness, psychiatric
             condition, behavioral disorder, alcoholism, drug abuse), medical history, physical
             findings, electrocardiogram findings, or laboratory abnormality that, in the
             Investigator's opinion, could adversely affect the safety of the participant, makes it
             unlikely that the course of treatment or follow-up would be completed, or could impair
             the assessment of study results.
Clinical trial NCT00189735 (phase 2, status: completed)
Conditions: kidney transplantation, renal transplantation, transplantation, renal, transplantation, kidney, grafting, kidney
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: fk778
SMILES: O\C(CCC#C)=C(\C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has end stage kidney disease or needs retransplantation (loss of graft for
             non-immunological reasons).

          -  Patient has been fully informed.

        Exclusion Criteria:

          -  Patient has an immunological high risk and/or having a previous graft survival shorter
             than 1 year due to immunological reasons.

          -  Patient has significant liver disease.

          -  Cold ischemia time of the donor kidney >28 hours.

          -  Patient having uncontrolled concomitant infections and/or severe diarrhoea, vomiting,
             active upper gastro-intestinal tract malabsorption or active peptic ulcer.

          -  Patient has previously received or is receiving an organ transplant other than kidney.
Clinical trial NCT00394069 (phase 2, status: completed)
Conditions: bronchiolitis
ICD codes: J21.9, J84.115, J21.1, J21.0, J21.8
Drugs: mk-0476, montelukast sodium
SMILES: OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria :

          -  Active bronchiolitis or a history of bronchiolitis and asthma-like symptoms

        Exclusion Criteria :

          -  A history of any significant illness that will pose additional risk to the patient
Clinical trial NCT00519077 (phase 2, status: completed)
Conditions: head and neck neoplasms
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  squamous cell carcinoma of the head and neck

          -  Tumour site that is amenable to biopsy. Patients can refuse biopsy and still
             participate in the study but all patients must have disease that can be biopsied

          -  Aged 18 years or older

          -  Prior epidermal growth factor receptor (EGFR) based therapy is allowed if greater than
             4 months have elapsed since last dose of that agent and study entry

          -  No chemotherapy or irradiation within the 28-day period preceding entry to the study.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Normal organ and marrow function

        Exclusion Criteria:

          -  Known severe hypersensitivity to Iressa or any of the excipients of this product

          -  Other co-existing malignancies or malignancies diagnosed within the last 3 years with
             the exception of basal cell carcinoma or cervical cancer in situ

          -  Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer
             therapy (except alopecia).

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the subject to participate in the trial

          -  Pregnancy or breast feeding women

          -  Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's
             Wort

          -  Treatment with a non-approved or investigational drug within 30 days before Day 1 of
             study treatment

          -  Any evidence of clinically active interstitial lung disease
Clinical trial NCT01284478 (phase 2, status: completed)
Conditions: pseudophakic cystoid macular edema,, diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: dexamethasone implant
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  DIABETIC PATIENTS WHO DEVELOP CYSTOID MACULA EDEMA AFTER CATARACT SURGERY (WITHIN 4-10
             WEEKS AFTER SURGERY

          -  VISUAL ACUITY WORSE THAN 20/32

        Exclusion Criteria:

          -  VISUAL ACUITY WORSE THAN 20/200

          -  MODERATE OR SEVERE GLAUCOMA (AS DEFINED AS USING >2 TOPICAL GLAUCOMA MEDIATIONS.

          -  USE OF SYSTEMIC, PERIOCULAR OR INTRAOCULAR CORTICOSTEROIDS WITHIN 30 DAYS OF
             ENROLLMENT
Clinical trial NCT01551147 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: ono-6950, placebo, montelukast
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients of both genders, between 18 to 60 years of age, with bronchial asthma
             symptoms for at least 6 months

          -  Patients with FEV1 ≥ 70% of predicted after withholding short-acting β agonists for at
             least 8 hours prior to testing

          -  Screening allergen challenge demonstrates that the patient experiences both an early
             and late asthmatic response

          -  Sensitivity to methacholine resulting in a ≥ 20% fall in FEV1 (PC20 methacholine)

          -  Non-smokers with free from the usage of nicotine-containing products at least for a
             year prior to screening

        Exclusion Criteria:

          -  Previous history of life-threatening asthma, respiratory tract infection and/or
             exacerbation of asthma within 6 weeks prior to the first screening visit

          -  Past or present disorders and diseases including, but are not limited to,
             cardiovascular, malignancy, hepatic, renal, hematological, neurological, psychiatric,
             endocrine, or pulmonary other than asthma

          -  Significant safety laboratory, ECG, or vital sign abnormalities that would place the
             patient at undue disk during the study procedures

          -  History of clinically significant multiple drug or food allergy
Clinical trial NCT00520403 (phase 2, status: completed)
Conditions: renal cell cancer
ICD codes: C96.20, C96.29, D47.09
Drugs: bevacizumab [avastin], interferon alfa-2a, vinblastine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  metastatic renal cell cancer of predominantly clear cell type;

          -  >=1 measurable lesion.

        Exclusion Criteria:

          -  prior treatment with chemotherapy, cytokine or tyrosine kinase inhibitor therapy for
             metastatic renal cell cancer;

          -  ongoing or recent need for full therapeutic dose of anticoagulants or chronic daily
             treatment with aspirin (>325mg/day);

          -  clinically significant cardiovascular disease.
Clinical trial NCT01218516 (phase 2, status: completed)
Conditions: adenocarcinoma of the lung
ICD codes: D02.20, D02.21, D02.22
Drugs: carboplatin, paclitaxel, pemetrexed, cisplatin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the lung classified as
             stage IV

          -  Confirmed folate receptor-alpha (FRA) expression by immunohistochemistry (IHC)

          -  Measurable disease with at least one unidimensionally measurable lesion according to
             RECIST criteria version 1.1 by computed tomography (CT) or magnetic resonance imaging
             (MRI) scans (CT or MRI scans must have been performed within 30 days prior to the
             first dose of farletuzumab or placebo)

          -  Must have received no prior chemotherapy, radiation therapy or surgery with curative
             intent for adenocarcinoma of the lung

        Exclusion Criteria:

          -  Participants who have had previous chemotherapy for adenocarcinoma of the lung

          -  Prior surgery with curative intent for adenocarcinoma of the lung

          -  Prior radiotherapy for adenocarcinoma of the lung. (Prior treatment with local
             radiotherapy for symptom control [i.e., palliative radiation with non-curative intent]
             is permitted)
Clinical trial NCT00593827 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ixabepilone, ixabepilone
SMILES: [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1, [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29
             (or CA15.3) ≥ 50

          -  Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer

          -  Prior chemotherapy is permitted with no limit on the number of prior regimens

          -  Two weeks or more have elapsed since last chemotherapy or radiation treatment

          -  Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2

          -  Is female, ≥ 18 yrs of age

          -  Protocol defined appropriate laboratory values

          -  Negative pregnancy test within 7 calendar days prior to registration

          -  Has signed a patient informed consent

        Exclusion Criteria:

          -  Had prior treatment with ixabepilone or other epothilones

          -  Has HER2+ disease

          -  Has a known, prior, severe (National Cancer Institute Common Terminology Criteria
             Adverse Events [NCI CTCAE] Grade 3-4) history of hypersensitivity reaction to a drug
             formulated in Cremophor ® EL (polyoxyethylated castor oil)

          -  Is receiving concurrent immunotherapy, hormonal therapy or radiation therapy

          -  Is receiving concurrent investigational therapy or has received such therapy within
             the past 30 days

          -  Has peripheral neuropathy > Grade 1

          -  Has evidence of central nervous system (CNS) involvement requiring radiation or
             steroid treatment. Participants with stable brain metastases who are off steroids at
             least 2 weeks are eligible

          -  Is pregnant or breast feeding
Clinical trial NCT00502801 (phase 2, status: completed)
Conditions: pneumonia, bacterial pneumonia, ventilator-associated pneumonia, infections, nosocomial
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0, J15.9, P23.6, J95.851
Drugs: doripenem
SMILES: [H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients suffering from Nosocomial Pneumonia or Ventilator-Associated Pneumonia

          -  All patients must be hospitalized throughout the treatment period

          -  Patients must have microbiological samples (respiratory secretions) suitable for
             culture and microscopy

        Exclusion Criteria:

          -  Known or suspected severe kidney impairment

          -  Known or suspected liver dysfunction

          -  Treatment with any investigational drug or device within 30 days before enrollment

          -  Patients with one or more of the following: cystic fibrosis, lung abscess, active
             tuberculosis

          -  Women who are pregnant or lactating
Clinical trial NCT00687323 (phase 2, status: completed)
Conditions: leukemia, acute myeloid, myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of acute myeloid leukemia (AML), any subtype except acute
             promyelocytic leukemia (APL), by the World Health Organization (WHO) criteria, or high
             risk MDS with blasts between 10 and 20% in the bone marrow.

          -  No prior AML chemotherapy except hydroxyurea.

          -  Leukemic blast count <30x10^9/L at the start of therapy. Prior cytoreduction with
             hydroxyurea (maximum 14 days) is permitted.

          -  Participant is not a candidate for aggressive induction based on at least one of the
             following: adverse-risk cytogenetics (complete or partial deletion of 5 or 7, complex
             [>3] cytogenetic abnormalities, inv3, 11q23 abnormalities); secondary AML (antecedent
             hematologic disorder or therapy-related AML); comorbid medical illnesses precluding
             standard induction therapy; participant's refusal of standard induction therapy.

          -  Confirmed low MGMT expression (MGMT: beta-actin ≤0.2), as evaluated by Western blot,
             or weak MGMT expression defined as > 0.2 and ≤2.5 if promoter is methylated, upon
             Sponsor approval.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          -  Use of medically approved contraception in fertile males and females.

          -  Negative urine or serum pregnancy test for women of childbearing potential (72 hours
             prior to Baseline).

        Exclusion Criteria:

          -  Serum bilirubin >2 times the upper limit of normal (ULN), or serum aspartate
             aminotransferase/ alanine aminotransferase >5 times ULN.

          -  Serum creatinine >200 umol/L.

          -  History of other malignancies within 1 year prior to study entry, with the exception
             of localized nonmelanomatous skin cancer or cervical cancer in situ.

          -  Presence of active uncontrolled infection.

          -  Known human immunodeficiency virus (HIV) infection.

          -  Any medical condition that may interfere with protocol evaluation or oral medication
             intake.

          -  Prior chemotherapy other than hydroxyurea.
Clinical trial NCT00508209 (phase 2, status: unknown status)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  First relapse after ASCT

          -  Symptomatic myeloma

          -  More than 2,0 x 10^6 CD34+ stem cells / kg bodyweight in the freezer for stem cell
             support

          -  Signed informed consent given prior to any study related activities have been
             performed

          -  Age > 18 years

        Exclusion Criteria:

          -  Allogeneic transplantation scheduled as a part of the treatment

          -  Expected survival of less than one month.

          -  Performance status (WHO) > 3

          -  Neuropathy > Grade 3 (neurological symptoms interfering with ADL)

          -  Non-secreting myeloma

          -  Other concurrent disease making bortezomib treatment unsuitable

          -  Positive pregnancy test (only applicable for women with childbearing potential)

          -  Has known or suspected hypersensitivity or intolerance to melphalan, dexamethasone,
             boron, mannitol, or heparin, if an indwelling catheter is used

          -  Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure
             (Attachment 6, NYHA Classification of Cardiac Disease), uncontrolled angina,
             clinically significant pericardial disease, or cardiac amyloidosis

          -  History of hypotension or has decreased blood pressure (sitting systolic blood
             pressure [SBP] <= 100 mmHg and/or sitting diastolic blood pressure [DBP] <= 60 mmHg)

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study

          -  Have received an experimental drug or used an experimental medical device within 4
             weeks prior to inclusion into the study
Clinical trial NCT00098852 (phase 2, status: unknown status)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: rosiglitazone maleate
SMILES: CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of differentiated thyroid cancer

               -  Locoregionally extensive and/or metastatic disease

               -  Inoperable disease

          -  Failed prior conventional therapy that included total/near-total thyroidectomy AND
             radioactive iodine I 131 ablation therapy

          -  Elevated thyroglobulin (Tg) levels (> 3 ng/mL on thyroid hormone OR > 10 ng/mL off
             thyroid hormone)

               -  Tg-antibody positive patients are eligible despite the Tg level

          -  Radioactive iodine (RAI) scan showing no or therapeutically insignificant (< 1%) RAI
             uptake after thyroid hormone withdrawal

               -  Scan performed within the past 18 months

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Hemoglobin ≥ 10 g/dL

          -  WBC ≥ 3,000/mm^3

          -  Platelet count ≥ 50,000/mm^3

        Hepatic

          -  ALT ≤ 2 times upper limit of normal

        Renal

          -  Creatinine ≤ 1.5 mg/dL

        Cardiovascular

          -  No New York Heart Association class III or IV cardiac disease

        Other

          -  Not pregnant

          -  No nursing within the past 3 months

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No allergy to thiazolidinediones

          -  No other malignancy except basal cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  More than 3 months since prior chemotherapy

        Endocrine therapy

          -  See Disease Characteristics

          -  No concurrent levothyroxine

        Radiotherapy

          -  See Disease Characteristics

          -  No prior cumulative dose of radioiodine ≥ 800 mCi

          -  Prior adjuvant or therapeutic external beam radiotherapy allowed

        Surgery

          -  See Disease Characteristics
Clinical trial NCT00580125 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: pf-00217830, aripiprazole, pf-00217830, pf-00217830
SMILES: O=C1CCC2=CC=C(OCCCCN3CCN(CC3)C3=CC=CC4=CC=CC=C34)N=C2N1, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, O=C1CCC2=CC=C(OCCCCN3CCN(CC3)C3=CC=CC4=CC=CC=C34)N=C2N1, O=C1CCC2=CC=C(OCCCCN3CCN(CC3)C3=CC=CC4=CC=CC=C34)N=C2N1
Eligibility criteria:

        Inclusion Criteria:

        Key inclusion criteria include:

          -  Have a current diagnosis of schizophrenia.

          -  Increase in symptoms over the past 2-4 weeks.

          -  Willing to remain inpatients for the duration of the trial.

        Exclusion Criteria:

          -  Subjects with a current DSM-IV axis I diagnosis other than schizophrenia

          -  Subjects who meet the DSM-IV criteria for psychoactive substance abuse and dependence

          -  Subjects with a history of treatment resistant schizophrenia

          -  Females of childbearing potential
Clinical trial NCT00340704 (phase 2, status: completed)
Conditions: bladder, neurogenic
ICD codes: G98.0, K59.2, M48.061, M48.062
Drugs: tamsulosin hydrochloride
SMILES: CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Neuropathic bladder secondary to known neurological disorder

          -  Elevated detrusor leak point pressures (LPP) ≥40 cm H2O confirmed by two measurements
             at baseline

        Exclusion Criteria:

          -  Clinically significant abnormalities as determined by the investigator

          -  A history of relevant orthostatic hypotension, fainting spells or blackouts